Kiadis Aims To Boost Stem Cell Transplant Market With Adjuvant Filing
Kiadis Pharma hopes to tap into a $1bn-plus commercial opportunity with its lead product ATIR101 in the treatment of blood cancer. ATIR101 has just been filed in Europe on the strength of data from single dose Phase II trial; a Phase III trial to pursue US approval is ongoing.
You may also be interested in...
Kiadis Pharma N.V. has presented positive data from its single dose Phase II trial with lead product ATIR101 for the treatment of blood cancers, clearing the way for the start of a randomized Phase III in the second half of the year. The trial met the primary endpoint of transplant-related mortality (TRM) at six months.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.